Consumer Discretionary

Amazon Pharmacy Reaping Benefits of Demand for Anti-Obesity Drugs, Executive Says

/ / Consumer Discretionary /

Amazon.com’s (AMZN) online pharmacy is reaping the benefits of demand for anti-obesity drugs in the US, the Financial Times reported, citing John Love, the head of the business. Drugs such as Eli Lilly’s (LLY) Zepbound and Novo Nordisk’s (NVO) Wegovy would create “a lot of revenue” for Amazon Pharmacy, said Love, the division’s general manager and vice president, according to the report. Both drugs are available directly through Amazon’s website, the FT said. Earlier in March, Eli Lilly and Amazon Pharmacy partnered to deliver widely used prescription drugs through the LillyDirect consumer services. The drugs include Eli Lilly’s obesity, diabetes and migraine headache medicines. Amazon said Tuesday it started same-day delivery for prescription medication in New York and greater Los Angeles using e-bikes, electric vans and drones.

Amazon Pharmacy Reaping Benefits of Demand for Anti-Obesity Drugs, Executive Says Read Post »

CFRA Reiterates Buy Opinion On Shares Of The Walt Disney Company

/ / Consumer Discretionary /

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We believe DIS has a rigorous plan to drive future growth and enterprise value leading to the April 3 shareholder meeting. We raise our target by $19 to $139 on a forward TEV/EBITDA of 14.1x our 2024 EBITDA estimate of $1.46B. Our multiple is well below the five-year historic average of 22.5x, but a premium to linear network peers that trade at high-single digits. We think DIS deserves a higher valuation for Experiences (parks and cruises lines) at 37% of FY 2023 (Sep.) revenue and 59% of operating income and leading Sports franchises (18%, 33%) with ESPN networks. The turnaround story centers around Entertainment’s (45%, 7%) film, television networks, and direct-to-consumer units with Disney+, ESPN+, and Hulu. We like that DIS is driving efficient content spending, as

CFRA Reiterates Buy Opinion On Shares Of The Walt Disney Company Read Post »

Nike Fiscal Q3 Earnings Decline, Revenue Rises; Shares Drop Premarket

/ / Consumer Discretionary /

Nike (NKE) reported fiscal Q3 earnings late Thursday of $0.77 per diluted share, down from $0.79 a year earlier. Analysts polled by Capital IQ forecast $0.71. Revenue for the quarter ended Feb. 29 was $12.43 billion, up from $12.39 billion a year earlier. Analysts surveyed by Capital IQ projected $12.30 billion. Shares of Nike slumped 6.6% in premarket activity Friday.

Nike Fiscal Q3 Earnings Decline, Revenue Rises; Shares Drop Premarket Read Post »

Lululemon Athletica Fiscal Q4 Earnings, Sales Rise But Q1, Full-Year Forecasts Miss Estimates; Shares Sink Premarket

/ / Consumer Discretionary /

Lululemon Athletica’s (LULU) shares slumped almost 13% in premarket activity Friday after the company’s guidance for sales and earnings for fiscal Q1 and the full financial year lagged the market’s expectations. The company reported fiscal Q4 net income late Thursday of $5.29 per diluted share, up from $0.94 a year earlier. Analysts polled by Capital IQ expected $5.03. Net revenue in the quarter ended Jan. 28 was $3.21 billion, up from $2.77 billion a year earlier. Analysts surveyed by Capital IQ expected $3.20 billion. The company expects fiscal Q1 diluted earnings of $2.35 to $2.40 a share on revenue of $2.18 billion to $2.20 billion. Analysts surveyed by Capital IQ expect EPS of $2.60 on revenue of $2.26 billion. The company expects full-year adjusted diluted earnings of $14 to $14.20 a share on revenue of $10.70 billion to $10.80 billion. Analysts surveyed by Capital IQ expect EPS of $14.29 on

Lululemon Athletica Fiscal Q4 Earnings, Sales Rise But Q1, Full-Year Forecasts Miss Estimates; Shares Sink Premarket Read Post »

Scroll to Top